Weight loss : While not the original purpose of these medications, many patients experience significant and sustained weight lossespecially those on higher-dose versions like Wegovy or Zepbound
Differential Alterations in Offset Analgesia and Conditioned Pain Modulation in Fibromyalgia: Evidence for Distinct Central Dysregulation
Association between Different GLP-1 Receptor Agonists and Gastrointestinal Adverse Reactions: A Real-World Disproportionality Study Based on FDA Adverse Event Reporting System Database. Frontiers in Endocrinology, vol
This might include: Keeping a detailed symptom diary during semaglutide initiation Establishing thresholds for concerning symptoms (bloody stools, fever, severe pain) Planning for prompt fecal calprotectin testing or limited sigmoidoscopy if symptoms worsen Scheduling more frequent follow-up during the first 3-6 months of therapy Alternative treatment options should be explored
final rule expected later in 2026 Approval guarantee: None - prescribing is the independent clinical judgment of the treating provider
Commercial patch safety concerns Without clinical trials or regulatory oversight, the safety profile of commercial patches is largely unknown: Ingredient quality : No verification of purity or potency Skin reactions : Adhesives and ingredients may cause irritation or allergic responses Interactions : Herbal components like berberine may interact with medications Undisclosed ingredients : Some patches may contain undeclared substances The MHRA doesnt evaluate these products before they reach the market, and adverse events arent systematically collected or reviewed
.png)
